Journal article
The efficacy and pharmacokinetics of terbinafine against the frog-killing fungus (Batrachochytrium dendrobatidis)
Alexandra A Roberts, Lee Berger, Sherryl G Robertson, Rebecca J Webb, Tiffany A Kosch, Michael McFadden, Lee F Skerratt, Beverley D Glass, Cherie A Motti, Laura A Brannelly
MEDICAL MYCOLOGY | OXFORD UNIV PRESS | Published : 2019
DOI: 10.1093/mmy/myy010
Abstract
Captive and wild amphibians are under threat of extinction from the deadly fungal pathogen Batrachochytrium dendrobatidis (Bd). The antifungal drug terbinafine (TBF) is used by pet owners to treat Bd-infected frogs; however, it is not widely used in academic or zoological institutions due to limited veterinary clinical trials. To assess TBF’s efficacy, we undertook treatment trials and pharmacokinetic studies to investigate drug absorption and persistence in frog skin; and then we correlated these data to the minimal lethal concentrations (MLC) against Bd. Despite an initial reduction in zoospore load, the recommended treatment (five daily 5 min 0.01% TBF baths) was unable to cure experiment..
View full abstractGrants
Awarded by Queensland Government Accelerate Fellowship
Awarded by Australian Research Council
Funding Acknowledgements
This work was supported by a Queensland Government Accelerate Fellowship [14-218 to A.A.R.] with additional funds from the Taronga Conservation Science Initiative and the Queensland Department of Environment and Heritage Protection; the Australian Research Council [FT100100375, LP110200240, DP120100811 to LFS and LB] with additional funds from industry partners Taronga Zoo and New South Wales Office of Environment and Heritage; the Advance Queensland Women's Academic Fund; and a Collaboration Across Boundaries Grant provided by James Cook University.